Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
anaplastic lymphoma kinase-directed chimeric antigen receptor t-cell therapy
- Development stage
- Preclinical
- Lead developer
- ALKemist Bio
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies
- Administration
- Intravenous
01
Overview
Anaplastic lymphoma kinase-directed chimeric antigen receptor t-cell therapy is an investigational cell therapy being developed by ALKemist Bio for the treatment of neuroblastoma. The therapy consists of T cells (either autologous or allogeneic) that are genetically engineered ex vivo to express a chimeric antigen receptor (CAR) targeting the extracellular domain of anaplastic lymphoma kinase (ALK). ALK is a receptor tyrosine kinase that is highly expressed as a membrane-bound protein on the surface of most neuroblastoma cells but is largely absent in normal adult tissues, making it a suitable target for immunotherapy. These CAR-T cells are designed to recognize membrane-expressed ALK and mediate T cell-driven cytotoxicity against tumor cells. Currently in preclinical development, this therapy is part of a dual approach by ALKemist Bio to target ALK-positive cancers, complementing their TCR-T platform which targets intracellular ALK fusion proteins.
- Other names
- ALK CAR-TALK-directed CAR-T cell therapy
02
Targets
ALK (Anaplastic lymphoma kinase receptor tyrosine kinase)
Beyond the preview
Go deeper on anaplastic lymphoma kinase-directed chimeric antigen receptor t-cell therapy.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on anaplastic lymphoma kinase-directed chimeric antigen receptor t-cell therapy.